Morepen Laboratories
Ticker > Company >

Morepen Laboratories share price

Morepen Laboratories Ltd.

NSE: MOREPENLAB BSE: 500288 SECTOR: Pharmaceuticals & Drugs  2.43 L   1.57 K   277

47.14
-2.65 (-5.32%)
NSE: 08 Aug 04:06 PM

Price Summary

Today's High

₹ 50.9

Today's Low

₹ 46.66

52 Week High

₹ 100.9

52 Week Low

₹ 42

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2583.05 Cr.

Enterprise Value

₹ 2560.77 Cr.

No. of Shares

54.8 Cr.

P/E

34.63

P/B

2.17

Face Value

₹ 2

Div. Yield

0.42 %

Book Value (TTM)

₹  21.71

CASH

₹ 50.48 Cr.

DEBT

₹ 28.19 Cr.

Promoter Holding

35.65 %

EPS (TTM)

₹  1.36

Sales Growth

14.84%

ROE

13.29 %

ROCE

17.71%

Profit Growth

139.9 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Morepen Laboratories Ltd.

Forever Young Burnol Lemolate Fibre-X QuickChek Exygra Itch Beat 2 Kool Hair Oil

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.84%
3 Year11.39%
5 Year16.48%

Profit Growth

1 Year139.9%
3 Year5.58%
5 Year31.13%

ROE%

1 Year13.29%
3 Year13.63%
5 Year15.71%

ROCE %

1 Year17.71%
3 Year16.86%
5 Year17.19%

Debt/Equity

0.0317

Price to Cash Flow

33.39

Interest Cover Ratio

43.4504

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 35.65 0.00
Mar 2025 35.65 0.00
Dec 2024 35.65 0.00
Sep 2024 35.65 0.00
Jun 2024 38.22 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 43.4504.
  • Company’s PEG ratio is 0.247537808475896.
  • The company has an efficient Cash Conversion Cycle of 22.2195 days.
  • Company has a healthy liquidity position with current ratio of 2.3903.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.5397998283702.

 Limitations

  • The company has shown a poor profit growth of 5.58433901091624% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.3927013584661% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 385.64 383.7 403.26 381.94 391.28
Total Expenditure 337.03 340.64 371.68 351.78 372.33
Operating Profit 48.61 43.07 31.58 30.16 18.95
Other Income 3.07 4.63 4.87 3.14 4.09
Interest 1.04 1.05 1.27 3.74 3.81
Depreciation 3.59 3.79 4.81 12.25 7.88
Exceptional Items 0 0 0 0 0
Profit Before Tax 47.05 42.86 30.38 17.3 11.35
Tax 12 10.93 7.69 5.39 3.29
Profit After Tax 35.05 31.93 22.69 11.91 8.06
Adjusted EPS (Rs) 0.69 0.58 0.41 0.22 0.15

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 791.99 1112.42 1449.27 1338.88 1537.59
Total Expenditure 727.52 1000.05 1320.13 1261.61 1375.77
Operating Profit 64.47 112.37 129.14 77.27 161.82
Other Income 9.42 11.77 20.03 5.76 12.57
Interest 1.97 1.79 2.43 1.98 3.51
Depreciation 34.43 28.11 21.19 18.01 21.9
Exceptional Items 0 0 0 0 0
Profit Before Tax 37.48 94.25 125.54 63.04 148.98
Tax 5.15 0 24.48 16.8 38.04
Net Profit 32.33 94.25 101.06 46.24 110.94
Adjusted EPS (Rs.) 0.72 2.1 2.12 0.9 2.17

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 89.96 89.96 95.56 102.23 102.23
Total Reserves 217.29 355.01 502.61 677.89 786.8
Borrowings 0.92 0.83 1.32 0.93 3.36
Other N/C liabilities 24.43 26.06 31.09 33.52 34.28
Current liabilities 329.38 375.63 402.69 290.98 352.64
Total Liabilities 661.99 847.5 1033.26 1105.54 1279.31
Assets
Net Block 134.84 144.02 156.11 170.82 216.54
Capital WIP 0 1.96 14.15 17.01 24.45
Intangible WIP 0 0 0 0 0
Investments 118.78 118.78 117.79 117.84 126.18
Loans & Advances 59.83 89.67 68.17 68.74 68.99
Other N/C Assets 0.28 0.27 0.28 0.28 0.24
Current Assets 348.26 492.79 676.76 730.85 842.91
Total Assets 661.99 847.5 1033.26 1105.54 1279.31
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 37.48 94.25 125.54 63.04 148.98
Adjustment 34.23 29.63 13.02 18.01 22.7
Changes in Assets & Liabilities -55.33 -74.56 -183.04 -166.9 -56.96
Tax Paid -5.52 0 -24.39 -16.27 -37.36
Operating Cash Flow 10.86 49.31 -68.87 -102.12 77.36
Investing Cash Flow -12.08 -69.09 -22.64 -36.2 -83.6
Financing Cash Flow 4.65 47.46 66.41 144.2 0.28
Net Cash Flow 3.43 27.68 -25.09 5.88 -5.96

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 38.22 35.65 35.65 35.65 35.65
aakriti suri 0.01 0.01 0.01 0.01 0.01
aanandi suri 0.15 0.14 0.14 0.14 0.14
aanchal suri 0.13 0.13 0.13 0.13 0.13
anju suri 1.01 0.95 0.95 0.95 0.95
anubhav suri 0.15 0.14 0.14 0.14 0.14
anubhav suri (arunsuri so... 0.29 0.27 0.27 0.27 0.27
brook investments and fin... 2.97 2.77 2.77 2.77 2.77
concept credits and consu... 3.00 2.80 2.80 2.80 2.80
epitome holdings pvt.ltd.... 2.84 2.65 2.65 2.65 2.65
gulfy malhotra 0.22 0.21 0.21 0.21 0.21
kanak suri 0.20 0.18 0.18 0.18 0.18
late p.l. suri - - 0.07 0.07 0.07
liquid holdings pvt. ltd.... 0.98 0.91 0.91 0.91 0.91
mamta suri 0.59 0.55 0.55 0.55 0.55
master arjun suri 0.14 0.13 0.13 0.13 0.13
mid med financial service... 2.93 2.73 2.73 2.73 2.73
rajas suri 0.03 0.03 0.03 0.03 0.03
rajas suri (kb surisons h... 0.19 0.18 0.18 0.18 0.18
react investments and fin... 2.92 2.73 2.73 2.73 2.73
sanjay suri 0.67 0.62 0.62 0.62 0.62
sanjay suri (sanjaysuri s... 0.41 0.38 0.38 0.38 0.38
sara suri 0.14 0.13 0.13 0.13 0.13
scope credits and financi... 3.05 2.84 2.84 2.84 2.84
seed securities and servi... 2.80 2.61 2.61 2.61 2.61
shalu suri 0.40 0.37 0.37 0.37 0.37
solace investments and fi... 2.95 2.75 2.75 2.75 2.75
solitary investments and ... 2.96 2.76 2.76 2.76 2.76
sonia pankaj bajaj 0.72 0.67 0.67 0.67 0.67
square investments and fi... 2.76 2.57 2.57 2.57 2.57
sunita suri 0.62 0.58 0.58 0.58 0.58
sushil suri 1.08 1.00 1.00 1.00 1.00
sushil suri (sushilsuri s... 0.24 0.22 0.22 0.22 0.22
varun suri 0.60 0.56 0.56 0.56 0.56
p.l. suri 0.08 0.07 - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 61.78 64.35 64.35 64.35 64.35
pinfold overseas limited 7.54 7.03 7.03 7.03 7.03
morepen laboratories limi... - 1.02 1.02 1.02 -
morepen laboratories limi... 1.09 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q2FY22
Concall Q1FY25
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q2FY20
Presentation Q1FY22
Presentation Q1FY21

Company News

Morepen Laboratories - Quaterly Results 6 Aug, 2:47 PM Morepen Laboratories - Quaterly Results 6 Aug, 2:47 PM Morepen Laboratories - Quaterly Results 6 Aug, 2:47 PM Morepen Laboratories’ arm to incorporate wholly owned subsidiary 25 Jul, 5:50 PM Morepen Laboratories incorporates step-down subsidiary in Dubai 23 Jul, 11:08 AM Morepen Laboratories incorporates wholly owned subsidiary in Dubai 19 Jun, 10:52 AM Morepen Laboratories informs about outcome of committee meeting 23 May, 12:25 PM Morepen Laboratories informs about newspaper publication 13 May, 5:31 PM Morepen Laboratories reports 29% fall in Q4 consolidated net profit 13 May, 12:29 PM Morepen Laboratories informs about press release 13 May, 12:21 PM Morepen Laboratories informs about audited financial results 12 May, 6:01 PM Morepen Laboratories - Quaterly Results 12 May, 3:54 PM Morepen Laboratories - Quaterly Results 12 May, 3:54 PM Morepen Laboratories - Quaterly Results 12 May, 3:54 PM Morepen Laboratories to launch new drug for Fatty Liver 29 Apr, 12:50 PM Morepen Laboratories gets nod to incorporate wholly owned subsidiary in Dubai 29 Apr, 10:09 AM Morepen Laboratories informs about press release 29 Apr, 9:40 AM Morepen Laboratories informs about launch of new products 24 Apr, 2:25 PM Morepen Laboratories informs about press release 11 Apr, 11:41 AM Morepen Laboratories informs about press release 1 Apr, 11:40 AM Morepen Laboratories secures Loratadine approval for export to China 1 Apr, 9:50 AM Morepen Laboratories incorporates step-down subsidiary 20 Mar, 6:02 PM Morepen Laboratories to transfer Medical Devices Business 19 Mar, 2:46 PM Morepen Laboratories launches Empamore 18 Mar, 9:29 AM Morepen Laboratories’ arm gets nod to form new subsidiary company 19 Feb, 2:51 PM Morepen Laboratories - Quaterly Results 6 Feb, 2:11 PM Morepen Laboratories - Quaterly Results 6 Feb, 2:11 PM Morepen Laboratories - Quaterly Results 6 Feb, 2:11 PM Morepen Laboratories informs about newspaper publication 18 Jan, 5:04 PM Morepen Laboratories to hive off medical devices business 15 Jan, 11:30 AM Morepen Laboratories incorporates subsidiary company 9 Jan, 9:44 AM Morepen Laboratories’ arm introduces weight management program ‘LightLife’ 11 Dec, 12:58 PM Morepen Laboratories - Quaterly Results 11 Nov, 2:28 PM Morepen Laboratories - Quaterly Results 11 Nov, 2:28 PM Morepen Laboratories - Quaterly Results 11 Nov, 2:28 PM Morepen Laboratories informs about loss of share certificates 23 Oct, 3:34 PM Morepen Laboratories informs about clarification on price movement 26 Aug, 12:40 PM Morepen Laboratories informs about earnings call transcript 17 Aug, 3:37 PM Morepen Laboratories informs about press release 12 Aug, 3:30 PM Morepen Laboratories - Quaterly Results 12 Aug, 10:04 AM Morepen Laboratories - Quaterly Results 12 Aug, 10:04 AM Morepen Laboratories - Quaterly Results 12 Aug, 10:04 AM Morepen Laboratories informs about press release 6 Aug, 9:56 AM Morepen Laboratories informs about loss of share certificates 22 Jun, 12:51 PM Morepen Laboratories - Quaterly Results 21 May, 7:05 PM Morepen Laboratories - Quaterly Results 21 May, 7:05 PM Morepen Laboratories informs about PCS certificate 23 Apr, 5:55 PM Morepen Laboratories informs about outcome of EGM 18 Mar, 4:13 PM Morepen Laboratories informs about outcome of board meeting 31 Jan, 3:59 PM Morepen Laboratories - Quaterly Results 31 Jan, 2:22 PM

Morepen Laboratories Stock Price Analysis and Quick Research Report. Is Morepen Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Morepen Laboratories and its performance over the period of time. Morepen Laboratories stock price today is Rs 47.14.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Morepen Laboratories cash from the operating activity was Rs 77.3627 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Morepen Laboratories has a Debt to Equity ratio of 0.0317 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Morepen Laboratories , the EPS growth was 139.9027 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Morepen Laboratories has OPM of 10.5241730015118 % which is a bad sign for profitability.
     
  • ROE: Morepen Laboratories have a average ROE of 13.2926 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Morepen Laboratories is Rs 47.14. One can use valuation calculators of ticker to know if Morepen Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Morepen Laboratories

Morepen Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Morepen Laboratories Ltd. is a leading pharmaceutical company in India that specializes in the manufacturing and supply of bulk drugs, formulations, diagnostics, and APIs. With a rich history of more than three decades, Morepen has established itself as a trusted name in the healthcare industry. The company is known for its commitment to quality, innovation, and customer satisfaction.

Morepen Laboratories Ltd. - Share Price

Stay updated with the latest share price of Morepen Laboratories Ltd. Our website provides real-time information on the stock's performance in the market. By tracking the share price, investors can make informed decisions regarding buying, selling, or holding their positions in Morepen Laboratories Ltd.

Morepen Laboratories Ltd. - Balance Sheet

Access the balance sheet of Morepen Laboratories Ltd. to get a comprehensive understanding of the company's financial position. Our pre-built screening tools enable investors to analyze the balance sheet and identify key financial indicators without the need for complex calculations. We provide downloadable annual reports that serve as a valuable resource for conducting a thorough analysis.

Morepen Laboratories Ltd. - Annual Report

The annual report of Morepen Laboratories Ltd. contains a wealth of information that can assist investors in evaluating the company's performance over the past year. Our website offers downloadable annual reports, enabling investors to gain insights into the company's financials, business strategies, and future prospects.

Morepen Laboratories Ltd. - Dividend

Discover the dividend history of Morepen Laboratories Ltd. by exploring our website. Investors interested in dividend income can track the company's dividend payouts over the years. Our platform provides a user-friendly interface where investors can access the latest dividend announcements and historical dividend data.

Morepen Laboratories Ltd. - Quarterly Result

Stay updated with the quarterly results of Morepen Laboratories Ltd. Our website provides access to the company's financial performance for each quarter. Investors can analyze the quarterly reports, along with our premium features such as fair value calculation using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Morepen Laboratories Ltd. - Stock Price

Track the stock price of Morepen Laboratories Ltd. and monitor its movement in the market on a daily basis. Our website provides a comprehensive chart that displays the historical price data, allowing investors to identify trends and patterns. By understanding the stock price dynamics, investors can make informed decisions about their investment in Morepen Laboratories Ltd.

Morepen Laboratories Ltd. - Price Chart

Our website offers an interactive price chart that allows investors to visualize the historical price movement of Morepen Laboratories Ltd. This tool enables users to analyze the stock's performance over different time frames and identify trends, support, and resistance levels. The price chart serves as a valuable resource for technical analysis.

Morepen Laboratories Ltd. - News

Stay updated with the latest news and developments related to Morepen Laboratories Ltd. Our website provides a dedicated news section where investors can access relevant news articles, press releases, and market updates. By staying informed, investors can make well-informed decisions based on the latest information.

Morepen Laboratories Ltd. - Concall Transcripts

Access the concall transcripts of Morepen Laboratories Ltd. to gain insights into the company's quarterly earnings calls and management discussions. Our platform offers downloadable concall transcripts, enabling investors to study the key highlights, decisions, and future plans discussed during these calls.

Morepen Laboratories Ltd. - Investor Presentations

Morepen Laboratories Ltd. regularly publishes investor presentations that provide an overview of the company's operations, financial performance, and growth prospects. Our platform offers downloadable investor presentations, allowing investors to delve into the details and understand the dynamics of Morepen Laboratories Ltd.

Morepen Laboratories Ltd. - Promoters

Learn about the promoters of Morepen Laboratories Ltd. and their contribution to the company's growth and success. Our website provides detailed information about the promoters, their background, and the roles they play in the company's management and decision-making processes.

Morepen Laboratories Ltd. - Shareholders

Discover the major shareholders of Morepen Laboratories Ltd. and their influence on the company's governance and strategic decisions. Our platform offers insights into the shareholding pattern of the company, providing investors with a holistic view of the ownership structure.

With our website’s comprehensive resources and pre-built screening tools, investors can conduct a thorough stock analysis of Morepen Laboratories Ltd. Make use of our downloadable annual reports, concall transcripts, investor presentations, and other valuable features to gain a deeper understanding of the company's financial health, market performance, and growth potential. 

Morepen Laboratories Balance Sheet Analysis

Morepen Laboratories Reserves Growth

Analyzing the data of Morepen Laboratories, the total reserves of the company have shown a notable upward trajectory from March 2020 to March 2024. Starting at Rs 217.29 Cr in March 2020, the reserves escalated to Rs 786.80 Cr by March 2024, reflecting solid financial reinforcement and retained earnings growth.

Morepen Laboratories Debt Overview

A glance at the borrowings reveals a minimal and well-managed debt profile for Morepen Laboratories. The borrowings fluctuated slightly over the years but remained low, peaking at Rs 3.36 Cr by March 2024, suggesting a conservative approach to leveraging and financial stability.

Morepen Laboratories Assets Expansion

The assets of Morepen Laboratories have witnessed a substantial increase indicating robust growth. The net block, which constitutes the tangible assets, expanded from Rs 134.84 Cr in March 2020 to Rs 216.54 Cr by March 2024. Concurrently, current assets rose significantly from Rs 348.26 Cr to Rs 842.91 Cr, underlining strong operational efficiency and liquidity.

This analysis derives from the Standalone Balance Sheet of Morepen Laboratories, reflecting its financial health and growth over the specified period.

Additionally, investors tracking the pharmaceutical sector on NSE/BSE indices may find Morepen Laboratories a potential candidate for their investment portfolio, given its solid balance sheet performance.

Read More
X